Cannabis
Cyios Corp. Executes Supply Agreement with Specialty Chemical Company to Access Proprietary Anti-Microbial Formulations for Numerous Applications Including Hand Sanitizer, Surface Cleaner and Laundry Care
Company Obtains FDA Registration and Receives NDC Numbers for its New “24” Brand Non-Alcohol Based, Long-Lasting Hand Sanitizer and Readies Online Retail Store for Initial Product Launch
Aventura, Florida–(Newsfile Corp. – May 20, 2020) – CYIOS Corp. (OTC Pink: CYIO), a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, is pleased to announce it has executed a multi-year supply agreement with a specialty chemical company dedicated to developing unique and proprietary anti-microbial sanitizing products. As part of the agreement, CYIOS now has access to a platform, for its own private label brand and sub-distributors, containing dozens of proprietary sanitizing and disinfecting products for personal, home and commercial use, formulated and enhanced with Zetrisil®.
Additionally, the Company has received notice its initial products, the “24” Brand Non-Alcohol based, fast-acting, long-lasting Hand Sanitizer Gel in 2oz and an 8oz containers, have been FDA Registered, with accompanying National Drug Code (NDC) numbers.
Mr. John O’Shea, Chairman of CYIOS Corp, stated, “We are pleased to have signed a multi-year supply agreement with a specialty chemical company that has developed a unique and proprietary platform of sanitizer products formulated and enhanced with Zetrisil®. Zetrisil® is a proprietary nano-based silicone compound which effectively protects and/or “shields” the area that “24” Brand hand sanitizer product is applied to from bacterial contamination by way of a long-lasting, cationic-charged, anti-microbial nano-silicone coating.”
He continued, “Our initial product launch will focus on the Hand sanitizer market with our bottling a 2oz and 8oz option for consumers which will be sold under the Brand “24”. We are in the final stage of launching our new online retail store and are excited to introduce the “24” Brand hand sanitizer product to market which is anticipated to occur over the next week. Since hand sanitizer is considered an over the counter drug, obtaining FDA Registration with accompanying NDC numbers is an important step in the process. We believe that having a compliant product, labeling containing Made in the USA and FDA Registered, are important product differentiators.”
“Through our supply agreement we are able to purchase the raw materials in bulk drums, rather than pay wholesale or fully packaged pricing. Our product will be filled at an FDA registered, inspected and cGMP manufacturer. Unlike traditional alcohol-based hand sanitizers, that are flammable or poisonous if accidently consumed, our “24” Brand hand sanitizer is family friendly with no harsh chemicals or alcohol, and won’t dry hands out from continuous use. Most significantly, our “24” Brand hand sanitizer is long-lasting and shown to be effective up to 24 hours with one application,” commented Mr. O’Shea.
“24” Brand Hand Sanitizer Gel Product Description
Up to 24 hours of protection against harmful germs: “24” Brand Hand Sanitizer Gel is formulated with Zetrisil®, a unique nano antimicrobial technology that not only kills on contact but also has a persistent activity that helps prevent re-contamination. The persistence of “24” Hand Sanitizer Gel has been shown to remain effective for up to 24 hours.
Kills 99.99% of harmful germs: “24” Hand Sanitizer Gel kills 99.99% of the harmful germs it comes in contact with by disrupting the outer cell membranes resulting in a physical kill. This physical kill ensures microorganisms don’t adapt or become resistant over time. “24” Hand Sanitizer Gel is a fast-acting, alcohol-free formula that kills germs, bacteria and viruses long-term, from just one application. Not only does “24” hand sanitizer eliminate germs that are present on the skin, the proprietary nano-protective barrier Zetrisil® offers a long-lasting shield of protection on the skin.
Alcohol-free formula: Most hand sanitizers contain high percentages of alcohol to poison germs, generally over 65%. This creates a highly flammable, poisonous mix that carries with it a risk for being ingested amongst other factors. Constant use of alcohol-based hand sanitizers also has the effect of drying out your skin, leading to irritation and cracking. “24” Hand Sanitizer Gel is water-based and contains no alcohol. It’s also non-flammable and non-poisonous, making it more effective & safer hand sanitizer for the whole family.
Moisturizes your hands with Aloe vera: “24” Hand Sanitizer Gel is a water-based sanitizer with added aloe vera to leave your hands feeling fresh and soft.
Mr. O’Shea concluded, “As economies around the world open back up, people all over the globe are faced with the reality of changing lifestyles and incorporating virus safety precautions as part of everyday life. Recent industry reports suggest that the worldwide market for hand sanitizers, at $2.7 Billion in 2019, could exceed $36 Billion by 2026. We anticipate that our 24 Brand Hand sanitizer with a longer-lasting formula that provides consumers, families and especially children with a safer alternative to alcohol-based sanitizer will grab market share in what appears to be large and growing market opportunity that’s here to stay for some time. Additional products we look to roll out in the near future include a hospital grade hard surface cleaner for industrial and commercial use, and a laundry care product, both having been tested to show sanitizing protection of up to a 28 days.”
CONTACT INFORMATION
John O’Shea at [email protected]
Investors are encouraged to follow CYIOS using:
www.twitter.com/cyioscorp
www.linkedin.com/company/cyios-corporation-llc
www.facebook.com/cyioscorporation
About ChoiceWellness, Inc
ChoiceWellness, Inc. is a health and wellness company that has brought to market the DR’s CHOICE line of products, as well as the “24” Brand Hand Sanitizer products. DR’s CHOICE was developed with a mission to offer Doctors and Medical Practitioners their own Professional Grade CBD BRAND with a suite of products they could stand behind and be confident to offer to their patients. Our customers can be assured that DR’s CHOICE CBD products have gone through the highest scrutiny of testing for purity, potency and quality. DR’s Choice products have been brought to market for Doctors and Medical Professionals seeking a better solution for patients suffering from pain, inflammation, anxiety or other persistent symptoms. For more information please visit www.choicewellnessbrands.com
About CYIOS Corporation
CYIOS Corporation is a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, including the DR’s CHOICE brand of products. The team has in-depth knowledge of the health and wellness markets, financial services industry, medical and health services, and blockchain. CYIOS is focused on the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. Further, the Company continues to seek and evaluate attractive business opportunities and to leverage its resources and expertise to build a diversified, sustainable business model. For more information please visit. https://www.cyioscorporation.com/
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements.” Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56207
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Indivior1 week agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
-
Cannabis3 days ago
One World Products Issues Shareholder Update Letter
-
Cannabis3 days agoIM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
